CAPR
Capricor Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-31/100
Last price
7.77
▼ 0.01 (0.13%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
7.79
Prev close
7.78
Day high
7.89
Day low
7.46
Volume
3.13M
Market cap
$450.58M
P/E (TTM)
—
52W range
2.96 – 40.37
Day trading desk
Gap from prior close
+0.13%
Prior close 7.78
VWAP
7.74
+0.33% from price
Relative volume
0.87×
Normal
Session range
5.90%
7.46 – 7.90
Position in range
70%
Near session high
ATR (14D)
0.78
10.08% of price
Prior day high
8.80
PDH
Prior day low
7.37
PDL
Bid / ask spread
—
Quote not published
Session volume
5.84M
Avg 6.74M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.57%
-11.5%
1M
-17.55%
-18.7%
3M
-65.17%
-69.7%
6M
-75.76%
-93.9%
YTD
-73.15%
-87.4%
1Y
+5.30%
-11.1%
3Y
+126.61%
+44.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CAPR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-7.83K
Net selling
Buy transactions
8
106.94K shares
Sell transactions
7
114.77K shares
Net transactions
+15
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
5.49M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 25, 26 | KRASNEY KAREN General Counsel |
SELL | 24.10K | $732.16K | Direct |
| Jun 25, 26 | BERGMANN ANTHONY Chief Financial Officer |
SELL | 24.10K | $732.16K | Direct |
| Jun 25, 26 | KRASNEY KAREN General Counsel |
CONVERSION | 24.10K | $76.64K | Direct |
| Jun 25, 26 | BERGMANN ANTHONY Chief Financial Officer |
CONVERSION | 24.10K | $76.64K | Direct |
| Jun 24, 26 | KRASNEY KAREN General Counsel |
SELL | 900 | $27.00K | Direct |
| Jun 24, 26 | BERGMANN ANTHONY Chief Financial Officer |
SELL | 900 | $27.00K | Direct |
| Jun 24, 26 | KRASNEY KAREN General Counsel |
CONVERSION | 900 | $2.86K | Direct |
| Jun 24, 26 | BERGMANN ANTHONY Chief Financial Officer |
CONVERSION | 900 | $2.86K | Direct |
| May 18, 26 | BERGMANN ANTHONY Chief Financial Officer |
CONVERSION | 3.00K | $4.17K | Direct |
| May 13, 26 | LITVACK FRANK I Director |
CONVERSION | 3.94K | $5.47K | Direct |
| May 1, 26 | KRASNEY KAREN General Counsel |
SELL | 25.00K | $792.55K | Direct |
| May 1, 26 | BERGMANN ANTHONY Chief Financial Officer |
SELL | 25.00K | $792.54K | Direct |
| May 1, 26 | KRASNEY KAREN General Counsel |
CONVERSION | 25.00K | $79.50K | Direct |
| May 1, 26 | BERGMANN ANTHONY Chief Financial Officer |
CONVERSION | 25.00K | $79.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERGMANN ANTHONY |
Chief Financial Officer | 11.22K | Sale |
COLLIER EARL M JR |
Director | 57.61K | Conversion of Exercise of derivative security |
DUNBAR GEORGE W JR |
Director | 14.31K | Conversion of Exercise of derivative security |
KRASNEY KAREN |
General Counsel | 30.55K | Sale |
LITVACK FRANK I |
Director | 180.05K | Conversion of Exercise of derivative security |
MARBAN LINDA |
Chief Executive Officer | 211.10K | Conversion of Exercise of derivative security |
SABAR KARIMAH ES |
Director | 0 | Sale |
Fundamentals
Market cap$450.58M
Enterprise value$303.69M
Revenue (TTM)—
Gross profit$-99.73M
EBITDA$-133.07M
Net income$-129.42M
EPS (TTM)$-2.45
Free cash flow$-89.19M
Total cash$237.93M
Total debt$91.05M
Book value / share$4.24
Shares outstanding58.14M
Float42.60M
Short % of float37.37%
Dividend yield0.00%
Beta (5Y)0.61
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.24
PEG ratio0.38
Price / sales—
Price / book1.83
EV / revenue—
EV / EBITDA-2.28
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-73.70%
Return on assets-33.63%
Debt / equity36.98
Current ratio7.35
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $22.27M | $25.18M | $2.55M | -100.0% |
| Operating revenue | $0 | $22.27M | $25.18M | $2.55M | -100.0% |
| Research & development | $84.45M | $49.97M | $36.45M | $21.82M | +69.0% |
| Selling, general & admin | $22.75M | $14.21M | $12.37M | $10.32M | +60.0% |
| Total operating expense | $108.14M | $64.83M | $49.26M | $32.25M | +66.8% |
| Operating income | -$108.14M | -$42.56M | -$24.08M | -$29.70M | -154.1% |
| Net interest income | -$3.05M | $0 | — | — | — |
| Pre-tax income | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -159.6% |
| Tax provision | $1.60K | $1.60K | — | — | 0.0% |
| Net income | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -159.6% |
| Net income to common | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -159.6% |
| Basic EPS | -2.26 | -1.15 | -0.83 | -1.18 | -96.5% |
| Diluted EPS | -2.26 | -1.15 | -0.83 | -1.18 | -96.5% |
| EBIT | -$102.00M | -$40.47M | -$24.08M | -$29.70M | -152.1% |
| EBITDA | -$100.11M | -$39.04M | -$23.01M | -$29.16M | -156.4% |
| Basic shares | 46.48M | 35.22M | 26.78M | 24.55M | +32.0% |
| Diluted shares | 46.48M | 35.22M | 26.78M | 24.55M | +32.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $287.85M | $11.29M | $14.69M | $9.60M | — | +2,450.3% |
| Cash & short-term investments | $318.13M | $151.52M | $39.49M | $41.42M | — | +110.0% |
| Accounts receivable | $59.17K | $10.37M | $10.37M | $547.58K | — | -99.4% |
| Total current assets | $322.94M | $163.39M | $50.86M | $42.89M | — | +97.7% |
| Property, plant & equipment | $31.85M | $6.87M | $7.61M | $6.94M | — | +363.3% |
| Goodwill & intangibles | — | — | — | — | $0 | — |
| Total assets | $355.95M | $170.48M | $58.73M | $50.09M | — | +108.8% |
| Total current liabilities | $35.84M | $21.03M | $31.27M | $23.59M | — | +70.4% |
| Total debt | $14.52M | $1.45M | $2.24M | $2.56M | — | +900.8% |
| Total liabilities | $50.16M | $25.02M | $36.13M | $38.31M | — | +100.5% |
| Retained earnings | -$304.88M | -$199.83M | -$159.37M | -$137.08M | — | -52.6% |
| Shareholder equity | $305.79M | $145.46M | $22.60M | $11.79M | — | +110.2% |
| Working capital | $287.10M | $142.36M | $19.59M | $19.30M | — | +101.7% |
| Net tangible assets | $305.79M | $145.46M | $22.60M | $11.79M | — | +110.2% |
| Shares issued | 57.37M | 45.58M | 31.15M | 25.24M | — | +25.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -159.6% |
| Depreciation & amortisation | $1.89M | $1.43M | $1.07M | $533.13K | +32.5% |
| Stock-based compensation | $17.23M | $9.77M | $7.39M | $4.46M | +76.4% |
| Change in working capital | $12.20M | -$10.78M | -$11.75M | $28.75M | +213.1% |
| Operating cash flow | -$69.81M | -$40.00M | -$25.60M | $4.92M | -74.5% |
| Capital expenditure | -$11.72M | -$1.54M | -$2.05M | -$3.36M | -661.8% |
| Investing cash flow | $97.48M | -$116.18M | $5.11M | -$35.07M | +183.9% |
| Financing cash flow | $248.89M | $152.77M | $25.58M | $4.87M | +62.9% |
| Free cash flow | -$81.54M | -$41.53M | -$27.64M | $1.56M | -96.3% |
| End cash position | $287.85M | $11.29M | $14.69M | $9.60M | +2,450.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $28.87M | $27.38M | $23.13M | $20.36M | $22.05M | — | +5.4% |
| Selling, general & admin | $13.81M | $9.14M | $5.78M | $5.68M | $5.42M | — | +51.1% |
| Total operating expense | $42.95M | $36.77M | $29.16M | $26.28M | $27.72M | — | +16.8% |
| Operating income | -$42.95M | -$36.77M | -$29.16M | -$26.28M | -$27.72M | — | -16.8% |
| Pre-tax income | -$40.73M | -$33.94M | -$30.17M | -$24.57M | -$25.91M | — | -20.0% |
| Tax provision | $1.60K | $0 | — | — | $1.60K | $0 | — |
| Net income | -$40.73M | -$33.94M | -$30.17M | -$24.57M | -$25.91M | — | -20.0% |
| Net income to common | -$40.73M | -$33.94M | -$30.17M | -$24.57M | -$25.91M | — | -20.0% |
| Basic EPS | -0.70 | -0.59 | -0.62 | -0.54 | -0.57 | — | -18.6% |
| Diluted EPS | -0.70 | -0.59 | -0.62 | -0.54 | -0.57 | — | -18.6% |
| EBIT | -$42.95M | -$36.77M | -$23.01M | -$26.28M | -$27.72M | — | -16.8% |
| EBITDA | -$42.38M | -$36.24M | -$22.51M | -$25.79M | -$27.23M | — | -17.0% |
| Basic shares | 57.93M | 57.43M | 48.85M | 45.72M | 45.71M | — | +0.9% |
| Diluted shares | 57.93M | 57.43M | 48.85M | 45.72M | 45.71M | — | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20.94M | $105.42M | $287.85M | $19.51M | $23.24M | — | -80.1% |
| Cash & short-term investments | $237.93M | $278.61M | $318.13M | $98.57M | $122.80M | — | -14.6% |
| Accounts receivable | — | $0 | $59.17K | $59.17K | $59.51K | $59.83K | — |
| Total current assets | $242.13M | $283.09M | $322.94M | $100.95M | $124.13M | — | -14.5% |
| Property, plant & equipment | $124.96M | $41.66M | $31.85M | $25.00M | $8.93M | — | +199.9% |
| Total assets | $368.74M | $326.28M | $355.95M | $126.44M | $133.57M | — | +13.0% |
| Total current liabilities | $32.96M | $33.64M | $35.84M | $28.15M | $28.40M | — | -2.0% |
| Total debt | $91.05M | $14.78M | $14.52M | $14.54M | $1.04M | — | +515.8% |
| Total liabilities | $122.52M | $47.58M | $50.16M | $42.57M | $28.59M | — | +157.5% |
| Retained earnings | -$379.55M | -$338.82M | -$304.88M | -$274.71M | -$250.14M | — | -12.0% |
| Shareholder equity | $246.22M | $278.70M | $305.79M | $83.87M | $104.98M | — | -11.7% |
| Working capital | $209.17M | $249.45M | $287.10M | $72.80M | $95.73M | — | -16.1% |
| Net tangible assets | $246.22M | $278.70M | $305.79M | $83.87M | $104.98M | — | -11.7% |
| Shares issued | 58.11M | 57.66M | 57.37M | 45.72M | 45.71M | — | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$40.73M | -$33.94M | -$30.17M | -$24.57M | -$25.91M | -20.0% |
| Depreciation & amortisation | $561.85K | $534.67K | $502.59K | $494.73K | $486.28K | +5.1% |
| Stock-based compensation | $6.06M | $5.92M | $3.84M | $4.00M | $3.65M | +2.4% |
| Change in working capital | $1.97M | -$2.04M | -$1.16M | $5.66K | $1.67M | +196.3% |
| Operating cash flow | -$31.49M | -$29.25M | -$23.57M | -$19.69M | -$20.12M | -7.6% |
| Capital expenditure | -$5.90M | -$10.75M | -$5.12M | -$4.01M | -$1.45M | +45.1% |
| Investing cash flow | -$48.76M | -$154.64M | $43.09M | $15.95M | $14.55M | +68.5% |
| Financing cash flow | -$4.24M | $1.47M | $248.82M | $6.95K | $19.58K | -388.5% |
| Free cash flow | -$37.39M | -$40.00M | -$28.69M | -$23.70M | -$21.57M | +6.5% |
| End cash position | $20.94M | $105.42M | $287.85M | $19.51M | $23.24M | -80.1% |
Options analytics
Put / call volume
1.20
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
6.00
-22.6% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
276
Contracts, this expiry
Put volume
330
Contracts, this expiry
Heaviest call OI
8.00
0 contracts
Heaviest put OI
6.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.58 | -0.70 | -21.6% |
| Mar 2026 | -0.54 | — | — |
| Dec 2025 | -0.55 | -0.62 | -12.4% |
| Sep 2025 | -0.54 | -0.54 | +0.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.42 | 8 | $10.40M | 0.0% |
| Next quarter | -0.10 | 8 | $27.92M | 0.0% |
| Current year | -1.45 | 9 | $55.69M | 0.0% |
| Next year | -1.48 | 9 | $56.54M | +1.5% |
Analyst targets & ownership
Mean target$27.00
High target$54.00
Low target$7.00
Implied upside247.51%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 3
Hold6
Sell / Strong sell0 / 0
Held by insiders9.44%
Held by institutions76.30%
Institutions holding239
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
8.58
-9.41% from price
SMA 20
8.69
-10.78% from price
SMA 50
7.51
+3.17% from price
SMA 100
16.25
-52.19% from price
SMA 200
22.51
-65.57% from price
EMA 12
8.56
-9.20% from price
EMA 26
8.78
-11.49% from price
EMA 50
10.34
-24.84% from price
RSI (14)
40.9
Neutral
MACD (12,26,9)
-0.22
Hist -0.05
ATR (14)
0.78
10.10% of price
Realised vol 30D
104.4%
Annualised
Bollinger upper
9.58
20, 2σ
Bollinger lower
7.79
20, 2σ
50 / 200 cross
Death
7.51 vs 22.51
Trend bias
Below 200
-65.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.00
Less volatile than market
Correlation to SPY
0.03
Largely independent
Realised vol 30D
104.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-89.1%
Peak to trough
Max drawdown 5Y
-89.1%
Peak to trough
ATR 14
0.78
10.10% of price
Beta (reported)
0.61
5Y monthly, from filing
Short interest
Shares short
19.68M
Prior 17.75M
Change vs prior
+10.8%
Shorts adding
% of float
37.37%
Heavily shorted
% of shares out
33.85%
Against total outstanding
Days to cover
2.6
Liquid
Float
42.60M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 26 | B. Riley Securities | UPGRADE | Neutral | Buy |
| Sep 1, 26 | Piper Sandler | UPGRADE | Neutral | Overweight |
| Aug 14, 26 | Cantor Fitzgerald | UPGRADE | Neutral | Overweight |
| Jul 31, 26 | Jones Trading | DOWNGRADE | Buy | Hold |
| Jul 30, 26 | Piper Sandler | DOWNGRADE | Overweight | Neutral |
| Jul 30, 26 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Jul 30, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| May 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 13, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Mar 13, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJun 5, 2019
Last split1:10
Split dateJun 5, 2019
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-24
Periodic Financial Reports
10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-06-08
Headlines
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
Stocktwits · 2d ago
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
GlobeNewswire · 2d ago
CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
Stocktwits · 6d ago
Top Premarket Gainers
MT Newswires · 7d ago
Why Did CAPR Stock Jump 20% After-Hours Today?
Stocktwits · 7d ago
Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
Simply Wall St. · 14d ago
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
GlobeNewswire · 20d ago
Sector Update: Healthcare Stocks Gain Late Afternoon
MT Newswires · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.